Ischemic stroke is a major health crisis causing high mortality and morbidity. The key treatment relies on the rapid intervention to dissolve thrombus, to reduce bleeding side effect and re-canalize clotted blood vessels using clot lysis drugs. Tissue plasminogen activator (tPA) is the only FDA-approved drug for ischemic stroke, but it has many limitations in clinical use. In recent years, the development of thrombolytic drugs and treatment strategies based on tPA has been progressed rapidly. Here we review the recent progress in this field, including the contributions from us and others, to promote the future development of novel thrombolytic drugs.
缺血性脑卒中是一种高发病率、高死亡率的重大健康危机。溶栓药物能快速溶解血栓、减少出血副作用、实现血管再通，对缺血性脑卒中治疗起到关键性的作用。重组组织纤溶酶原激活剂 (rtPA) 是FDA 批准的唯一缺血性脑卒中药物，但在临床使用中有诸多限制。近年来，基于tPA 的溶栓药物及治疗策略发展迅速，文中结合笔者课题组及目前国内外的相关研究成果，回顾了该领域的最新进展，为新型溶栓药物发展提供科学依据和思路。.
Keywords: ischemic stroke; thrombolysis; tissue plasminogen activator.